ClinicalTrials.gg
Active, not recruitingNCT06128356Updated Mar 4, 2026

Pilot Study of Dexmedetomidine Sublingual Film for the Ambulatory Treatment of Hyperadrenergic Autonomic Crisis in Patients With Familial Dysautonomia

A Phase 2 interventional study of Dexmedetomidine Sublingual in Familial Dysautonomia, sponsored by NYU Langone Health. Active, not recruiting at 1 site in United States. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-03-04.

Sponsored by NYU Langone Health · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
5
Allocation
Not applicable
Ages
18 Years to 80 Years
Sex
All
01

Study summary

This is a pilot open-label study to evaluate the feasibility of conducting a clinical trial using sublingual dexmedetomidine sublingual film to treat hyperadrenergic autonomic crises in patients with Familial Dysautonomia at home. The primary aims are to examine the feasibility of performing a clinical trial using dexmedetomidine at home to terminate autonomic crisis, and refine the interventions and assessments used to evaluate autonomic crisis termination.

02

Conditions studied

  • Familial Dysautonomia
03

In context

Lead sponsor

NYU Langone Health is the lead sponsor of 1,431 studies on the registry; 258 are open to participants now.

Of its 235 completed or terminated interventional studies of FDA-regulated products, 197 (84%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Genetically confirmed diagnosis of Familial Dysautonomia.
  • Evidence of autonomic crisis, previous treatment with IV dexmedetomidine without significant side effects, and registered medical data within the year preceding the study in our database.
  • One or more autonomic crises during the last year.
  • Age above 18 years.
  • The patient has a responsible caretaker to communicate with the medical providers.
  • Provision of signed and dated form from the patient and responsible caregiver.
  • Able to state willingness to comply with all study procedures and availability for the duration of the study
  • For males and females of : use condoms for if sexually active.

Exclusion criteria

Exclusion Criteria:

  • At the consideration of the principal investigator, the caregiver cannot fully understand the protocol or communicate during the crisis with the Center.
  • The patient during the crisis, before taking the medication, has any of the following:
  • a. Oxygen saturation less than 92% on room air or baseline need for oxygen, change from baseline oxygen dependency.
  • b. Respiratory rate >20 breaths per minute.
  • c. Supine blood pressure ≤ 90/60mmHg
  • d. Febrile illness with temperature >100.3 F.
  • e. Serological signs of infection (WBC count >10 g/dL, or CRP >10 mg/L or ESR>20, or above their steady historical baseline levels) in recent (less than one month) studies.
  • The patient is a female and has a positive pregnancy test.
  • score \<25 points.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
5 participants (actual)

Study arms

  • Experimental
    Sublingual dexmedetomidine

    Participants will be administered two 60 micrograms sublingual films of IGLMI following start of an autonomic crises. The maximum amount for the study is four oral films of 60 micrograms in 24 hours, two at the beginning of the crises and if needed, two additional within two hours.

    Drug: Dexmedetomidine Sublingual

Interventions

06

What researchers measure

Primary outcomes

  1. Number of subjects screened per month

    Time frame: Month 6

  2. Number of subjects enrolled per month

    Time frame: Month 6

  3. Number of completed crises treated at home within the protocol

    Time frame: Month 6

  4. Number of subjects that underwent an autonomic crisis per month

    Time frame: Month 6

  5. Average duration of the study from visit 1 to the last visit of the last patient

    Time frame: From enrollment to end of treatment (up to 6 months)

Secondary outcomes

  1. Length of time from autonomic crisis onset to the initiation of the video recording

    Time frame: Up to 2 hours

  2. Length of time from autonomic crisis onset to administration of the medication

    Time frame: Up to 2 hours

  3. Length of time from autonomic crisis onset to crisis resolution

    Time frame: Up to 24 hours

  4. Length of time it took to complete assessments from start of autonomic crisis

    Time frame: Up to 24 hours

  5. Percentage of completion of all rating scales

    The scales required to be completed is the Autonomic Crisis Symptom Assessment Scale (ACSAS), the study safety assessments and the Richmond Agitation-Sedation Scale.

    Time frame: Month 6

  6. Change in blood pressure

    Time frame: Pre-dose, up to 2 hours post-dose

  7. Change in heart rate

    Time frame: Pre-dose, up to 2 hours post-dose

  8. Change in number of vomiting episodes

    Time frame: Pre-dose, up to 2 hours post-dose

  9. Change in number of retching episodes

    Time frame: Pre-dose, up to 2 hours post-dose

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: Yes — The de-identified participant data from the final research dataset used in the published manuscript will be shared upon reasonable request beginning 9 months and ending 36 months following article publication or as required by a condition of awards and agreements supporting the research provided the investigator who proposes to use the data executes a data use agreement with NYU Langone Health. Requests may be directed to: Alejandra.gonzalez-duarte@nyulangone.org. The protocol and statistical analysis plan will be made available on Clinicaltrials.gov only as required by federal regulation or as a condition of awards and agreements supporting the research

Time frame: Beginning 9 months and ending 36 months following article publication or as required by a condition of awards and agreements supporting the research.

Access criteria: The investigator who proposed to use the data will be provided access upon reasonable request. Requests should be directed to Alejandra.gonzalez-duarte@nyulangone.org. To gain access, data requestors will need to sign a data access agreement.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jun 2024 (actual). Primary completion is estimated for Sep 2028, 51 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 7, 2023
First posted
Nov 13, 2023
StartActual
Jun 1, 2024
Primary completionEst.
Sep 2028
CompletionEst.
Dec 2028
Last update
Mar 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 4, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06128356
Lead sponsor
NYU Langone Health
Responsible party
Sponsor
First posted
Nov 13, 2023
Start date
Jun 1, 2024
Primary completion
Sep 2028 (estimated)
Completion
Dec 2028 (estimated)
Last update
Mar 4, 2026

Study contacts

Alejandra Gonzalez-Duarte, MD
principal investigator · NYU Langone Health

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dexmedetomidine

Start the discussion